Evogene Ltd.
EVGN
Positions held
Your positionsEVGN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $6.30M | Enterprise value | $7.24M | Trailing P/E | — | Forward P/E | -0.66 |
| PEG | — | Price / book | -1.64 | Beta | 0.72 | Dividend yield | 0.00% |
| Revenue growth | -60.7% | Earnings growth | — | Gross margin | -67.6% | Operating margin | -6.1% |
| Profit margin | 0.0% | ROE | -1.8% | ROA | -37.5% | Debt / equity | 0.36 |
| Current ratio | 3.57 | Free cash flow | -$1.98M | Analyst recommendation | strong_buy | Mean target | $2.15 |
| 52w high | $1.49 | 52w low | $0.35 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.3M | $0.3M | $0.3M | $0.3M | $0.5M | — |
| Op margin | -738.6% | -943.1% | -1659.9% | -873.1% | -489.1% | — |
| Net income | -$1.8M | -$5.9M | -$5.3M | $3.9M | -$4.5M | — |
| Gross margin | 40.6% | 61.1% | -627.4% | 49.7% | 74.5% | — |
| Gross profit | $0.1M | $0.2M | -$2.0M | $0.2M | $0.4M | — |
| Operating income | -$2.6M | -$3.1M | -$5.2M | -$2.7M | -$2.6M | — |
- Revenue +4% vs prior quarter ($0.3M vs $0.3M).
- Gross margin 40.6% (was 61.1% prior quarter).
- Operating margin expanded to -738.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $3.9M | $5.6M | $3.0M | $1.7M |
| Op margin | -364.2% | -336.3% | -744.6% | -1608.4% |
| Net income | -$8.5M | -$16.5M | -$23.9M | -$26.6M |
| Gross margin | -6.3% | 57.3% | 50.0% | 45.7% |
| Gross profit | -$0.2M | $3.2M | $1.5M | $0.8M |
| Operating income | -$14.0M | -$18.8M | -$22.2M | -$26.9M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors
2026-09-30 · Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
2026-08-31 · Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward
2026-08-27 · EverGen Infrastructure Reports Q2 2026 Results
2026-08-25 · Evogene (EVGN) Q2 2026 Earnings Call Transcript
2026-08-19 · Evogene Ltd. Q2 2026 Earnings Call Summary
2026-08-18 · Evogene Ltd (EVGN) (Q2 2026) Earnings Call Highlights: Strategic Pivot to AI-Driven Drug ...
2026-08-18 · Evogene Reports Second Quarter and First Half 2026 Financial Results
2026-08-18 · Evogene: Q2 Earnings Snapshot
2026-08-17 · Cibus Inc: Interoc Expands Rice Trade to 5 Traits, 36% Revenue Growth – Quarterly Update Report
Price (daily)
Full chart · RSI · MACD · patterns